PMID- 12020972
OWN - NLM
STAT- MEDLINE
DCOM- 20020708
LR  - 20190826
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 126
IP  - 1-2
DP  - 2002 May
TI  - Interferon-beta treatment alters peripheral blood monocytes chemokine production 
      in MS patients.
PG  - 205-12
AB  - Chemokines direct the recruitment of leukocytes to inflammatory sites and may 
      also participate in the regulation of cytokine production by naive T helper 
      cells. Chemokine production by blood monocytes was investigated by 
      intracytoplasmic staining in interferon-beta (IFN-beta)-treated multiple 
      sclerosis (MS) patients, untreated MS patients, and healthy controls. Under 
      unstimulated conditions, no differences in the production of interleukin-8 
      (IL-8), IFN-inducible protein 10 (IP-10), monokine induced by interferon-gamma 
      (Mig), monocyte chemoattractant protein-1 (MCP-1), and monocyte chemoattractant 
      protein-3 (MCP-3) were seen between untreated MS patients and controls. Chemokine 
      production by monocytes following T cell activation was decreased in MS patients 
      taking IFN-beta compared to controls and untreated MS patients. Unlike other 
      chemokines, macrophage inflammatory protein-1alpha (MIP-1alpha) production by 
      monocytes was significantly decreased in untreated MS patients compared to 
      controls, and IFN-beta treatment increased MIP-1alpha expression to the level 
      seen in controls. In vitro addition of IFN-beta1b to peripheral blood mononuclear 
      cells (PBMC) cultures tended to decrease the production of IL-8, IP-10, Mig, 
      MCP-1, and MCP-3, but not of MIP-1alpha. These findings suggest that IFN-beta 
      treatment may have a differential affect on chemokine production by monocytes. 
      Longitudinal studies must be done to confirm these observations.
FAU - Comabella, Manuel
AU  - Comabella M
AD  - Center for Neurologic Diseases, Brigham and Women's Hospital, 77 Avenue Louis 
      Pasteur, HIM 714, Boston, MA 02115, USA.
FAU - Imitola, Jaime
AU  - Imitola J
FAU - Weiner, Howard L
AU  - Weiner HL
FAU - Khoury, Samia J
AU  - Khoury SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (CCL7 protein, human)
RN  - 0 (CXCL9 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL7)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokine CXCL9)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Cytokines)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Interleukin-8)
RN  - 0 (Monocyte Chemoattractant Proteins)
RN  - 130068-27-8 (Interleukin-10)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Adult
MH  - CD40 Ligand/immunology
MH  - Chemokine CCL2/biosynthesis
MH  - Chemokine CCL7
MH  - Chemokine CXCL10/biosynthesis
MH  - Chemokine CXCL9
MH  - Chemokines, CXC/biosynthesis
MH  - Cytokines/*biosynthesis
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - *Intercellular Signaling Peptides and Proteins
MH  - Interferon-beta/*administration & dosage
MH  - Interleukin-10/immunology
MH  - Interleukin-8/biosynthesis
MH  - Male
MH  - Monocyte Chemoattractant Proteins/biosynthesis
MH  - Monocytes/*drug effects/immunology/metabolism
MH  - Multiple Sclerosis/*drug therapy/immunology
MH  - T-Lymphocytes/immunology
EDAT- 2002/05/22 10:00
MHDA- 2002/07/09 10:01
CRDT- 2002/05/22 10:00
PHST- 2002/05/22 10:00 [pubmed]
PHST- 2002/07/09 10:01 [medline]
PHST- 2002/05/22 10:00 [entrez]
AID - S0165572802000644 [pii]
AID - 10.1016/s0165-5728(02)00064-4 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2002 May;126(1-2):205-12. doi: 10.1016/s0165-5728(02)00064-4.